Corporate g.html

General information about company		
Scrip code	532167	
Name of the entity	OMKAR PHARMACHEM LIMITED	
Date of start of financial year	01-04-2017	
Date of end of financial year	31-03-2018	
Reporting Quarter	Quarterly	
Date of Report	31-12-2017	
Risk management committee	Not Applicable	

Annexure I		
Annexure I to be submitted by listed entity on quarterly basis		
I. Composition of Board of Directors		
Disclosure of notes on composition of board of directors explanatory		
Is there any change in information of board of directors compare to previous quarter	No	

Annexure 1		
II. Composition of Committees		
Disclosure of notes on composition of committees explanatory		
Is there any change in information of committees compare to previous quarter	No	

Annexure 1						
An	Annexure 1					
III.	III. Meeting of Board of Directors					
Disclosure of notes on meeting of board of directors explanatory						
Sr	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)			
1	29-08-2017					
2	14-09-2017		15			
3		14-12-2017	90			

	Annexure 1						
IV.	Meeting of Co	nmittees					
	Disclosure of notes on meeting of committees explanatory						
Sr	Name of Committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)	Name of other committee
1	Audit Committee	14-12-2017	Yes		14-09-2017	90	
2	Nomination and remuneration committee		Yes		29-08-2017		
3	Stakeholders Relationship Committee		Yes		29-08-2017		

	Annexure 1				
<b>V.</b> ]	V. Related Party Transactions				
Sr	Subject	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.		
1	Whether prior approval of audit committee obtained	NA			
2	Whether shareholder approval obtained for material RPT	NA			
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA			

	Annexure 1				
VI	VI. Affirmations				
Sr	r Subject				
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes			
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes			
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes			
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes			
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 100 listed entities)	NA			
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes			

Signatory Details	
Name of signatory	Anurag Sharma
Designation of person	Managing Director
Place	Delhi
Date	13-01-2018